

# From policy to practice: pharmacist bridges regulatory intent and real-world biosimilar uptake

## A pharmacist-driven model to boost biosimilar switching in hospital following the 2024 Swiss policy change

Marion Duwez<sup>1</sup>, Yassine Dhif<sup>1</sup>, Jean-Louis Frossard<sup>2</sup>, Jörg D. Seebach<sup>3</sup>, Pascal Bonnabry<sup>1,4</sup>

<sup>1</sup>Pharmacy, Geneva University Hospitals

<sup>2</sup>Gastroenterology, Geneva University Hospitals

<sup>3</sup>Division of Immunology and Allergy, Geneva University Hospitals

<sup>4</sup>Institute of Pharmaceutical Sciences of Western Switzerland, School of pharmaceutical sciences, University of Geneva


### Objectives

- Promoting the use of biosimilars to reduce drug costs for healthcare system
- Increasing the switch rate for biosimilars in gastroenterology and immunology
- Identifying and managing current barriers to switch

### Conclusions

- Administrative burdens under Art. 71ad, OAMal continue to impede biosimilar adoption, resulting in continued originator prescriptions without clinical justification or patient refusal
- Pharmacists play a pivotal role in improving switch rates by guiding prescribers, managing insurer approvals, and addressing patient concerns through targeted education

### Design




### Results

Study period: 8.02.2024 to 20.12.2024

n=17 OD patients scheduled (n=1 initiation)  
n=1 excluded (missing data)

- ♀: 10 / 17 (19-85 Y.O.)
- OD treatment for 1 to >10 years
- OD molecules: n=8 infliximab; n=8 rituximab; n=1 adalimumab
- Infusion every 2 to 52 weeks
- Disease: n=10 immunology; n=7 gastroenterology
- N=2 patient interviews: n=1 SF and n=1 SO
- Switch accepted: 75%



Switch refused:

N=3: patient or physician refused switch discussion  
N=1: previous perceived loss of efficacy

Delayed switches before pharmacist intervention:

N=3 transition from pediatric or community care  
N=4 unexplained delays  
N=3 insurance approval issues resolved by pharmacist  
N=1 prescription error corrected by pharmacist

Switchback:

N=1 (SF): perceived loss of efficacy after 2 BD infusions (nocebo effect?)

Retention rate: 92%  
↑ of hospital cost savings: CHF 50,000 / year

